A paper by Proudman et al. (2024) It is found that it will be very expensive to do so.
During the duration of 2018-22, all pregnant, clinical and post-anumodadan R&D activities were estimated to maintain the average life cycle level of 49.4 approved drugs in all disease areas, $ 139.6 billion dollars. With only pre-launch costs, the total annual cost of development for all drugs is $ 110.9 billion. These figures are not capitalized.
3 Innovation was stable by designations, the total annual estimated R&D cost for all approved first-in-class drugs was $ 55.6 billion; All approved advance-in-class drugs were $ 25.6 billion; And all approved joint-to-class drugs were $ 58.2.1 billion (for 3 categories for $ 139.6BN).
Compared to NIH funding for the financial year 2022, the total estimated life cycle of development was equal to 302% of the entire budget or 25 times larger than the dedicated budget, which was currently spent by NIH spending on approximate clinical research activities by GAO Used to be.
It also assumes that NIH will be able to choose the winners in the context of the best ROI clinical investments as well as the private sector, which is not possible that you can read the details of full paper and methods here.
